Head-To-Head Contrast: Acrivon Therapeutics (NASDAQ:ACRV) versus Ernexa Therapeutics (NASDAQ:ERNA)

Ernexa Therapeutics (NASDAQ:ERNA) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, profitability, valuation, dividends and earnings.

Institutional & Insider Ownership

70.6% of Ernexa Therapeutics shares are owned by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are owned by institutional investors. 1.5% of Ernexa Therapeutics shares are owned by company insiders. Comparatively, 11.9% of Acrivon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Ernexa Therapeutics has a beta of 6.25, indicating that its stock price is 525% more volatile than the S&P 500. Comparatively, Acrivon Therapeutics has a beta of 1.73, indicating that its stock price is 73% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Ernexa Therapeutics and Acrivon Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ernexa Therapeutics	1	0	0	0	1.00
Acrivon Therapeutics	1	1	4	1	2.71

Acrivon Therapeutics has a consensus target price of $11.00, suggesting a potential upside of 347.15%. Given Acrivon Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Acrivon Therapeutics is more favorable than Ernexa Therapeutics.

Valuation and Earnings

This table compares Ernexa Therapeutics and Acrivon Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ernexa Therapeutics	$580,000.00	15.70	-$44.54 million	($3.01)	-0.39
Acrivon Therapeutics	N/A	N/A	-$80.56 million	($2.13)	-1.15

Ernexa Therapeutics has higher revenue and earnings than Acrivon Therapeutics. Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ernexa Therapeutics and Acrivon Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ernexa Therapeutics	N/A	-1,950.55%	-304.60%
Acrivon Therapeutics	N/A	-53.71%	-48.31%

Summary

Acrivon Therapeutics beats Ernexa Therapeutics on 9 of the 13 factors compared between the two stocks.

About Ernexa Therapeutics

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.